- AVF Academy
- EAVLA Advanced Phlebology Webinar: January 2025
When is it safe to operate on varicose veins after superficial vein thrombosis, and can foam match heat for closing incompetent veins? In this Advanced Phlebology webinar, hosted by the Egyptian African Venous Lymphatic Association (EAVLA) with the American Venous Forum and the Journal of Vascular Surgery: Venous and Lymphatic Disorders, authors present recent research and an international panel weighs in.
What you’ll learn
- How superficial vein thrombosis is treated in everyday practice: in the INSIGHTS-SVT study, most patients received anticoagulation and compression, with fondaparinux for 45 days as the primary option, while varicose vein surgery rose from about 2 percent at baseline to 7 percent at three months
- Why waiting at least three months before surgery after superficial vein thrombosis lets inflammation settle, and why any urgent operation should be paired with anticoagulation
- How polidocanol endovenous microfoam compares with thermal ablation: a network meta-analysis found no significant difference in vein closure or deep vein thrombosis risk, and higher closure odds than physician-compounded foam, with results holding from 12 months to six years
- Perspectives from an international expert panel during discussion and audience Q&A
Agenda
- Welcome, Dr. Ruth Bush, AVF President and Editor in Chief of JVS-VL
- Varicose vein surgery after acute isolated superficial vein thrombosis: the INSIGHTS-SVT study, Dr. Thomas Noppeney
- Polidocanol endovenous microfoam versus thermal ablation: a network meta-analysis, Dr. Lowell Kabnick
- Expert discussion and Q&A
Faculty
- Rashad Bishara (Host), President, EAVLA
- Ruth Bush, AVF President and Editor in Chief, JVS-VL
- Thomas Noppeney, University Hospital Regensburg, Germany
- Lowell S. Kabnick
- Tomasz Urbanek, Professor and Vascular Surgeon, Medical University of Silesia, Katowice, Poland
- David Dexter
- Willy Chi
- Joseph Raffetto
- Marald Wikkeling
- Wassila Taha
Recorded live January 18, 2025. Supported by Kreussler Pharma.
Related
Junctional Reflux, Ablation Outcomes, and Early TOTEM Trial Results: Advanc... Junctional Reflux, Ablation Outcomes, and Early TOTEM Trial Results: Advanced Phlebology Webinar
Nov 16, 2026
Learn how junctional reflux affects the success of endovenous ablation for great saphenous vein insufficiency and the first r... more details Dec 6, 2025
Learn when to use venoactive drugs such as micronized purified flavonoid fraction, why ablation length matters more than moda... more details May 24, 2025
Learn five-year outcomes of ultrasound-guided foam sclerotherapy for saphenous trunk incompetence, how to treat the sub-ulcer... more details Translating Clinical Evidence Into Practice: Venclose™ System Real-world Da... Translating Clinical Evidence Into Practice: Venclose™ System Real-world Data & Expert Case Perspectives
Nov 10, 2026
Watch American Venous Forum experts review 30-day real-world outcomes for the Venclose radiofrequency ablation (RFA) system i... more details 


